609 related articles for article (PubMed ID: 29990695)
21. Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues.
Wong GL; Chan HL; Lo AO; Chan HY; Tse CH; Chim AM; Wong VW
Antivir Ther; 2013; 18(8):979-86. PubMed ID: 23744529
[TBL] [Abstract][Full Text] [Related]
22. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.
Boni C; Janssen HLA; Rossi M; Yoon SK; Vecchi A; Barili V; Yoshida EM; Trinh H; Rodell TC; Laccabue D; Alfieri A; Brillo F; Fisicaro P; Acerbi G; Pedrazzi G; Andreone P; Cursaro C; Margotti M; Santoro R; Piazzolla V; Brunetto MR; Coco B; Cavallone D; Zhao Y; Joshi A; Woo J; Lau AH; Gaggar A; Subramanian GM; Massetto B; Fung S; Ahn SH; Ma X; Mangia A; Ferrari C
Gastroenterology; 2019 Jul; 157(1):227-241.e7. PubMed ID: 30930022
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB.
Yan W; Wu D; Wang X; Chen T; Lai Q; Zheng Q; Jiang J; Hou J; Han M; Ning Q
Antivir Ther; 2015; 20(6):591-602. PubMed ID: 25814467
[TBL] [Abstract][Full Text] [Related]
24. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B.
Xu D; Fu J; Jin L; Zhang H; Zhou C; Zou Z; Zhao JM; Zhang B; Shi M; Ding X; Tang Z; Fu YX; Wang FS
J Immunol; 2006 Jul; 177(1):739-47. PubMed ID: 16785573
[TBL] [Abstract][Full Text] [Related]
25. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
26. Changes of Treg and Th17 cells balance in the development of acute and chronic hepatitis B virus infection.
Xue-Song L; Cheng-Zhong L; Ying Z; Mo-Bin W
BMC Gastroenterol; 2012 May; 12():43. PubMed ID: 22548790
[TBL] [Abstract][Full Text] [Related]
27. [Alterations of IFN-γ and IL-4 of peripheral blood T cells in patients with chronic HBV infection].
Li M; Sun X; Zhou Z; Zhang X; Jin S; Gao Y; Gao Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Feb; 32(2):240-4. PubMed ID: 26927386
[TBL] [Abstract][Full Text] [Related]
28. Decreased CD122 on CD56
Han W; Ni Q; Liu K; Yao Y; Zhao D; Liu X; Chen Y
Life Sci; 2018 Feb; 195():53-60. PubMed ID: 29307521
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
30. Intrahepatic natural killer cell activation, but not function, is associated with HBsAg levels in patients with HBeAg-negative chronic hepatitis B.
Tjwa ET; Zoutendijk R; van Oord GW; Biesta PJ; Verheij J; Janssen HL; Woltman AM; Boonstra A
Liver Int; 2014 Mar; 34(3):396-404. PubMed ID: 23890390
[TBL] [Abstract][Full Text] [Related]
31. The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B.
Demirören K; Kocamaz H; Doğan Y
Turk J Gastroenterol; 2015 Jan; 26(1):36-41. PubMed ID: 25698269
[TBL] [Abstract][Full Text] [Related]
32. Effect of entecavir on CD4+ T-cell subpopulations in patients with chronic hepatitis B.
Tian ZF; You ZL; Yi H; Kuang XM; Wang YM
Ann Hepatol; 2016; 15(2):174-82. PubMed ID: 26845594
[TBL] [Abstract][Full Text] [Related]
33. Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion.
Bruder Costa J; Dufeu-Duchesne T; Leroy V; Bertucci I; Bouvier-Alias M; Pouget N; Brevot-Lutton O; Bourliere M; Zoulim F; Plumas J; Aspord C;
PLoS One; 2016; 11(6):e0158297. PubMed ID: 27348813
[TBL] [Abstract][Full Text] [Related]
34. [Relationship between the changes in immune cells and HBeAg loss following antiviral treatment in chronic hepatitis B patients].
Zheng Q; Zhu YY; Chen J; Liu YR; You J; Zeng DW; Lin S; Jiang JJ
Zhonghua Gan Zang Bing Za Zhi; 2012 Nov; 20(11):801-6. PubMed ID: 23206296
[TBL] [Abstract][Full Text] [Related]
35. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
Gish RG; Chang TT; Lai CL; de Man RA; Gadano A; Llamoso C; Tang H
Antivir Ther; 2013; 18(5):691-8. PubMed ID: 23510982
[TBL] [Abstract][Full Text] [Related]
36. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B.
Tjwa ET; van Oord GW; Hegmans JP; Janssen HL; Woltman AM
J Hepatol; 2011 Feb; 54(2):209-18. PubMed ID: 21095036
[TBL] [Abstract][Full Text] [Related]
37. Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN α-2a therapy.
Cao W; Lu H; Zhang L; Wang S; Deng W; Jiang T; Lin Y; Yang L; Bi X; Lu Y; Zhang L; Shen G; Liu R; Chang M; Wu S; Gao Y; Hao H; Xu M; Chen X; Hu L; Xie Y; Li M
Front Immunol; 2022; 13():1067362. PubMed ID: 36479104
[TBL] [Abstract][Full Text] [Related]
38. Tfh cell-mediated humoral immune response and HBsAg level can predict HBeAg seroconversion in chronic hepatitis B patients receiving peginterferon-α therapy.
Zhang L; Zhang M; Li H; Chen Z; Luo A; Liu B; Chen M; Peng M; Ren H; Hu P
Mol Immunol; 2016 May; 73():37-45. PubMed ID: 27037894
[TBL] [Abstract][Full Text] [Related]
39. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
[TBL] [Abstract][Full Text] [Related]
40. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
